PMID-40085108 — Hwang: Lifetime Cost-Effectiveness of Tirzepatide and Semaglutide (JAMA Health Forum)

[DRAFT — authored 2026-04-19. Citation web-verified 2026-04-19 against PubMed and JAMA Health Forum.]

Citation

Hwang JH, Laiteerapong N, Huang ES, Kim DD. Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults. JAMA Health Forum. 2025;6(3):e245586. doi: 10.1001/jamahealthforum.2024.5586. PMID: 40085108. PMCID: PMC11909610.

External URL: JAMA Health Forum article

Phase 1 manifest note: Manifest listed this as "JAMA Health Forum Lifetime Cost-Effectiveness 2025" without a specific PMID. Web-verification 2026-04-19 confirmed PMID: 40085108, PMCID PMC11909610, published March 7, 2025. The per-QALY figures specified in the manifest ($197,023 tirzepatide; $467,676 semaglutide) match the published values.

Study Design

Design: Lifetime Markov cohort simulation (cost-effectiveness analysis)
Perspective: US healthcare sector
Comparators: Lifestyle modification alone vs four anti-obesity medications (naltrexone-bupropion, phentermine-topiramate, semaglutide, tirzepatide) each as adjunct to lifestyle
Population: US adults eligible for anti-obesity pharmacotherapy per FDA BMI criteria
Outcomes: Lifetime QALYs, direct medical costs, incremental cost-effectiveness ratio (ICER) per QALY gained

Key Findings

Incremental Cost-Effectiveness Ratios (at current net prices)

Agent (as adjunct to lifestyle)	ICER per QALY gained
Naltrexone-bupropion	Cost-saving
Phentermine-topiramate	Cost-effective at <$100K/QALY
Tirzepatide	$197,023/QALY
Semaglutide	$467,676/QALY

Cost-Effectiveness Probability (at $100K/QALY threshold)

Naltrexone-bupropion: 89.1% probability of being cost-effective
Tirzepatide and semaglutide: 0% probability of cost-effectiveness across all QALY threshold ranges examined at current net prices

Price Concessions Required

To reach the $100,000/QALY threshold:

Tirzepatide: 30.5% additional price reduction required
Semaglutide: 81.9% additional price reduction required

Clinical Benefit Magnitude

Tirzepatide produced the largest incremental QALY gain — 0.35 QALYs above lifestyle alone — reflecting the weight-loss and cardiometabolic benefit magnitude. The cost-effectiveness constraint is pricing, not clinical benefit.

Clinical Relevance

Hwang 2025 establishes that at current net prices, neither tirzepatide nor semaglutide meets conventional US cost-effectiveness thresholds for chronic weight management in the general obesity population. The finding is consistent with several prior US cost-effectiveness analyses and informs:

Payer coverage policy: Prior-authorization tightening, utilization-management criteria, and formulary restrictions align with this evidence
Patient out-of-pocket discussions: Patients facing self-pay or high co-insurance should understand the per-QALY price context
The discount-level conversation: ~30% net-price reduction for tirzepatide or ~80% for semaglutide would change the cost-effectiveness verdict at the $100K/QALY threshold

Triangulation with ICER 2025:

Hwang (JAMA Health Forum): Per-QALY values at current net prices exceed $100K/QALY threshold.
ICER 2025 Final Report: Found "high" long-term value for money at current pricing, with health benefit price benchmarks in the $8,300-$16,100/year envelope depending on agent/formulation.

The two analyses reach different value verdicts because of methodological differences: durability assumptions, comorbidity-prevention value, price-concession modeling, and health-benefit benchmarking approach. Both are legitimate; practitioners and payers should be familiar with both framings.

Limitations (Author-acknowledged)

Current net prices subject to change (discounts evolve); ICERs are price-sensitive
Durability assumption of continued treatment over lifetime; adherence/persistence heterogeneity simplified
Comorbidity-prevention value captured but model-dependent
Real-world effectiveness (vs trial efficacy) simplified
Patient heterogeneity (e.g., super-responders, non-responders) averaged

Evidence Level

Level II (Oxford CEBM for economic evaluations) — decision-analytic cost-effectiveness analysis.

Linked Peptides

Related References

REG-ICER-Obesity-2025 – ICER Final Evidence Report Semaglutide Tirzepatide (complementary independent value assessment)
PMID-40953447 – Betensky Knee OA Cost-Effectiveness (indication-specific cost-effectiveness companion)

Orchestrator Notes

Citation web-verified 2026-04-19; all manifest-stated figures confirmed against published article.
Primary citation for Cost-of-Care Analysis clinical reference.
Paired with ICER 2025 Final Evidence Report in triangulated cost framing for Lesson 5.4.

PMID-40085108 – Hwang JAMA Health Forum Lifetime Cost-Effectiveness